国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2013年
3期
207-210
,共4页
马玉萍%韩晓宇%刘倩%丁乾%苏进义%张海超
馬玉萍%韓曉宇%劉倩%丁乾%囌進義%張海超
마옥평%한효우%류천%정건%소진의%장해초
胃癌方%化疗%脾胃虚寒%胃癌%临床疗效
胃癌方%化療%脾胃虛寒%胃癌%臨床療效
위암방%화료%비위허한%위암%림상료효
Self-designed Chinese prescription%Chemotherapy%Stomach and spleen deficient cold type%Stomach cancer%Clinical efficacy
目的 观察自拟胃癌方联合化疗治疗晚期脾胃虚寒型胃癌的临床疗效.方法 采用随机数字表法将100例晚期脾胃虚寒型胃癌患者随机分为两组各50例.对照组采用化疗治疗,治疗组在对照组的基础上同时给予中药胃癌方配合治疗.连续治疗3个月后,观察两组患者的近期疗效、生活质量改善、体质量变化、外周血象、免疫功能改善以及不良反应发生情况及治疗后1年、3年、5年的患者生存率.结果 ①近期疗效:治疗后两组总有效率分别为60.0％ (30/50)、30.0％(15/50),治疗组明显优于对照组(Z=-2.100,P＜0.05)；②生活质量:两组患者生活质量提高率分别为64.0％ (32/50)和20.0％ (10/50),治疗组优于对照组(Z=-3.259,P＜0.05)；③体质量:治疗前后两组体质量变化好转率分别为24.0％ (12/50)和16.0％ (8/50),两组比较差异无统计学意义(Z=-1.815,P＞0.05)；④外周血象:治疗组50例中外周血象异常21例,对照组50例均有外周血象异常,两组比较差异有统计学意义(Z=-4.286,P＜0.05)；⑤免疫功能变化比较:两组治疗后CD4+、CD8+T淋巴细胞、NK细胞活性[治疗组分别为(40.8±4.1)％、(26.1±3.2)％、(83.57±2.52)％;对照组分别为(31.7±2.9)％、(33.8±3.0)％、(92.88±3.83)％]均较同组治疗前[治疗组分别为(34.2±3.5)％、(31.0±2.0)％、(85.01±2.92)％；对照组分别为(34.0±3.2)％、(30.9±2.2)％、(85.02±3.48)％]明显改善(P＜0.01或0.05).治疗后治疗组CD4+、CD8+、CD4+/CD8+和NK细胞活性与对照组比较,差异均有统计学意义(P＜0.01)⑥不良反应:治疗组不良反应发生率明显低于对照组,差异有统计学意义(Z=-5.297,P＜0.05)；⑦存活率比较:治疗组治疗后1年、3年、5年的生存率明显高于对照组,差异有统计学意义(x2值分别为5.263、12.96、7.895,P均＜0.05).结论 自拟胃癌方联合化疗药物治疗晚期脾胃虚寒型胃癌可有效缓解患者临床症状,提高机体免疫力,提高生活质量,延长生存时间.
目的 觀察自擬胃癌方聯閤化療治療晚期脾胃虛寒型胃癌的臨床療效.方法 採用隨機數字錶法將100例晚期脾胃虛寒型胃癌患者隨機分為兩組各50例.對照組採用化療治療,治療組在對照組的基礎上同時給予中藥胃癌方配閤治療.連續治療3箇月後,觀察兩組患者的近期療效、生活質量改善、體質量變化、外週血象、免疫功能改善以及不良反應髮生情況及治療後1年、3年、5年的患者生存率.結果 ①近期療效:治療後兩組總有效率分彆為60.0％ (30/50)、30.0％(15/50),治療組明顯優于對照組(Z=-2.100,P＜0.05)；②生活質量:兩組患者生活質量提高率分彆為64.0％ (32/50)和20.0％ (10/50),治療組優于對照組(Z=-3.259,P＜0.05)；③體質量:治療前後兩組體質量變化好轉率分彆為24.0％ (12/50)和16.0％ (8/50),兩組比較差異無統計學意義(Z=-1.815,P＞0.05)；④外週血象:治療組50例中外週血象異常21例,對照組50例均有外週血象異常,兩組比較差異有統計學意義(Z=-4.286,P＜0.05)；⑤免疫功能變化比較:兩組治療後CD4+、CD8+T淋巴細胞、NK細胞活性[治療組分彆為(40.8±4.1)％、(26.1±3.2)％、(83.57±2.52)％;對照組分彆為(31.7±2.9)％、(33.8±3.0)％、(92.88±3.83)％]均較同組治療前[治療組分彆為(34.2±3.5)％、(31.0±2.0)％、(85.01±2.92)％；對照組分彆為(34.0±3.2)％、(30.9±2.2)％、(85.02±3.48)％]明顯改善(P＜0.01或0.05).治療後治療組CD4+、CD8+、CD4+/CD8+和NK細胞活性與對照組比較,差異均有統計學意義(P＜0.01)⑥不良反應:治療組不良反應髮生率明顯低于對照組,差異有統計學意義(Z=-5.297,P＜0.05)；⑦存活率比較:治療組治療後1年、3年、5年的生存率明顯高于對照組,差異有統計學意義(x2值分彆為5.263、12.96、7.895,P均＜0.05).結論 自擬胃癌方聯閤化療藥物治療晚期脾胃虛寒型胃癌可有效緩解患者臨床癥狀,提高機體免疫力,提高生活質量,延長生存時間.
목적 관찰자의위암방연합화료치료만기비위허한형위암적림상료효.방법 채용수궤수자표법장100례만기비위허한형위암환자수궤분위량조각50례.대조조채용화료치료,치료조재대조조적기출상동시급여중약위암방배합치료.련속치료3개월후,관찰량조환자적근기료효、생활질량개선、체질량변화、외주혈상、면역공능개선이급불량반응발생정황급치료후1년、3년、5년적환자생존솔.결과 ①근기료효:치료후량조총유효솔분별위60.0％ (30/50)、30.0％(15/50),치료조명현우우대조조(Z=-2.100,P＜0.05)；②생활질량:량조환자생활질량제고솔분별위64.0％ (32/50)화20.0％ (10/50),치료조우우대조조(Z=-3.259,P＜0.05)；③체질량:치료전후량조체질량변화호전솔분별위24.0％ (12/50)화16.0％ (8/50),량조비교차이무통계학의의(Z=-1.815,P＞0.05)；④외주혈상:치료조50례중외주혈상이상21례,대조조50례균유외주혈상이상,량조비교차이유통계학의의(Z=-4.286,P＜0.05)；⑤면역공능변화비교:량조치료후CD4+、CD8+T림파세포、NK세포활성[치료조분별위(40.8±4.1)％、(26.1±3.2)％、(83.57±2.52)％;대조조분별위(31.7±2.9)％、(33.8±3.0)％、(92.88±3.83)％]균교동조치료전[치료조분별위(34.2±3.5)％、(31.0±2.0)％、(85.01±2.92)％；대조조분별위(34.0±3.2)％、(30.9±2.2)％、(85.02±3.48)％]명현개선(P＜0.01혹0.05).치료후치료조CD4+、CD8+、CD4+/CD8+화NK세포활성여대조조비교,차이균유통계학의의(P＜0.01)⑥불량반응:치료조불량반응발생솔명현저우대조조,차이유통계학의의(Z=-5.297,P＜0.05)；⑦존활솔비교:치료조치료후1년、3년、5년적생존솔명현고우대조조,차이유통계학의의(x2치분별위5.263、12.96、7.895,P균＜0.05).결론 자의위암방연합화료약물치료만기비위허한형위암가유효완해환자림상증상,제고궤체면역력,제고생활질량,연장생존시간.
Objeetive To investigate the clinical efficacy of treating stomach cance belonging to spleen and stomach deficient cold type with self-designed formula and chemotherapy.Methods 100 patients of stomach cancer belonging to stomach and spleen deficient cold were randomly grouped into a control group and a treatment group,with 50 cases in each group.The control group was only treated with chemotherapy,and the treatment group was additionally treated with self-designed Chinese formula on the basis of the control group.After 3 months' treatment,the curative effect,the improvement of life quality,the changes of body weight,the improvement of peripheral blood and immune function,and the occurrence of adverse reaction were observed.The survival rate of patients after 1,3 and 5 years' treatment was investigated.Results ① Short term curative effect:the total effectiveness of the control group and the treatment group was 60.0％ (30/50) and 30.0％ (15/50) respectively,with the treatment group being better than the control group(Z=-2.100,P＜0.05);② life quality:theimprovement rate of life quality in the treatment group and the control group was 64.0％ (32/50) and 20.0％ (10/50) respectively,with the treatment group being better than the control group (Z=-3.259,P＜0.05); ③ body weight:the improvement rate of body weight in the treatment group and the control group was 24.0％ and 16.0％ respectively,and there was no significant difference (Z=-1.815,P＞0.05) ; ④ peripheral blood:the peripheral blood abnormality rates of treatment group was obviously lower than the control group (Z=-4.286,P＜0.05) ;⑤ immune function changes:CD4+、CD8+、and the activity of NK cell of two groups after the treatment [the treatment group was (40.8 ± 4.1)％,(26.1-3.2)％,(83.57-2.52)％ respectively; the control group was (31.7±2.9)％、(33.8±3.0)％、(92.88±3.83)％ respectively] wasobviously improved compared with the same group before the treatment [the treatment group was (34.2±3.5)％,(31.0±2.0)％,(85.01±2.92)％ respectively; the control group was (34.0±3.2)％,(30.9±2.2)％,(85.02± 3.48) ％ respectively].The immune indexes (CD4+、CD8++、CD4+/CDg+and the activity of NK cell)in the treatment group presented significant difference (P＜0.01) than the control group after the treatment.⑥adverse reaction:compared with the control group,the occurrence rate of adverse reaction of the treatment group was obviously lower than the control group,and there was significant difference (Z=-5.297,P＜0.05).⑦survival rate:the survival rate of patients after 1,3 and 5 years' treatment in the treatment group was better than the control group,and there was significant difference (x2=5.263,12.96,7.895,P＜0.05).Conclusion The combination of self-designed Chinese formula and chemotherapy could effectively relieve the clinical symptoms,improve the immunity,reduce the occurrence of adverse reaction,and improve the life quality of patients with stomach cancer belonging to stomach and spleen deficient cold type.
